characteristics associated with patients' risk of cancer-specific mortality (CSM). Kaplan-Meier analysis was used to evaluate recurrence free survival (RFS).
INTRODUCTION AND OBJECTIVES: Patients who undergo radical cystectomy for urothelial cancer are at risk for upper tract urothelial carcinoma (UTUC). It is well-accepted that the removal of a formal bladder cuff at the time of radical nephroureterectomy (RNU) results in improved oncologic outcomes. However, the effects of ileal mucosal cuff excision in patients undergoing RNU who have had a prior urinary diversion has not been studied. To our knowledge, we present the first report on outcomes of ileal mucosal cuff management for patients undergoing RNU for UTUC.
METHODS: Between 1995 and 2009 we retrospectively reviewed 483 patients at Mayo Clinic who underwent RNU for primary UTUC. We identified 41 patients who underwent RNU after having a previous radical cystectomy. Patients with mucosal cuff excision identified pathologically were analyzed and compared to those without a mucosal cuff. Kaplan Meier analyses were used to estimate recurrence free survival.
RESULTS: Median age of the cohort was 72 (IQR 66, 77) and 32 (78%) were male. A total of 18 (43.9%) patients underwent ileal cuff excision. Tumor multifocality, non-muscle invasive tumors (<pT1), and ureteral tumors were seen more frequently in patients who underwent cuff excision. Between the two groups there was no significant difference in intra-operative, 5 (27.8%) cuff vs. 6 (26.0%) no cuff, or postoperative complications, 4 (23.5%) vs. 8 (44.4%) no cuff (p¼0.90 and p¼0.19; respectively). At a median follow up of 47 months, there was no significant difference in 4-year recurrence free survival between the mucosal cuff excision and no mucosal cuff groups (20.4% vs. 30.4%; p¼0.61). Moreover, the rate of recurrence in the ileal conduit was comparable between the two groups, 1 (5.5%) cuff vs 3 (13%) no cuff (p¼0.41).
CONCLUSIONS: We found no significant difference in oncologic outcomes between patients with ileal mucosal cuff excision and those without a mucosal cuff at the time of RNU. Furthermore, there was no significant increase in intra-or post-operative complications by removing the mucosal cuff. In well-selected patients, oncologic outcomes may not be compromised by lack of ileal cuff excision. is arguably a valid option for management of bladder cancer in selected cases. The majority of reported studies however have short term follow up as well as small sample size. We aimed to evaluate retrospectively our long term experience of prostate sparing cystectomy and compare it with our results of nerve sparing cystoprostatectomy (NSCP) in the laparoscopic/robotic era METHODS: Between 2001 and 2011, 60 patients were treated with laparoscopic or robotic PSC for muscle invasive or recurrent non muscle invasive bladder cancer. These patients were matched and compared to 47 patients who received laparoscopic or robotic NSCP and orthotopic bladder substitution during the same study period. Regarding continence, surviving patients were postoperatively contacted, at 3 months and 1 year, to answer a questionnaire based on the International Continence Society guidelines for reporting continence after urinary diversion. Potency was accessed by a house made questionnaire addressing the use of any medications or devices to achieve erection.
Source of Funding: None
RESULTS: Mean patient age was 60.35 and 62.12 for PSC and NSCP respectively. Median follow up was 69.5 months and 62 months for PSC and NSCP respectively. Forty percent of PSC had ¼ pT1N0, 30% pT2N0, 22% ¼ pT3N0 while 8% had N+ disease; compared to NSCP patients whom 38% had ¼pT1N0, 19% pT2N0, 23% ¼ pT3N0 and 19% N+. (p¼0.74) The overall 3-and 5-year cancer specific survivals were 92% and 90% in the PSC group, and 82% and 79% in the NSCP group respectively. The local recurrence rates were 11.7 % and 21.3 % for the PSC and the NSCP groups respectively, and the respective distant recurrence rate was 17% and 28%. Regarding continence; 45% in the PSC showed immediate and full recovery of continence day and night compared to no patient in the NSCP group.
After 1 year, 97% and 71% of PSC group were completely leak-free for day and night respectively, compared to 78% and 37% in NSCP (p¼0.001). The incidence of self catheterization was equal in both groups at 15%. On long term follow up, 42% of PSC patients developed symptoms secondary to outlet obstruction and 18% of them required endoscopic resection of their prostate. While in NSCP patients, 4% developed anastomotic stricture that required endoscopic fulgration (p¼0.001) Regarding potency; 49% of PSC and 23% of NSCP reported maintaining similar preoperative potency level. Sexual intercourse was achievable without any treatment in 68% of PSC compared to 37% in NSCP. The incidence of intracavernosal injection was higher in the NSCP arm compared to the PSC (41% vs.17%) Four patients (9%) in the NSCP group failed all conservative management and required penile prosthesis compared to no patient in the PSC group. ( p¼0.001) CONCLUSIONS: Prostate sparing cystectomy is superior to nerve-sparing cystoprostatectomy regarding continence and potency. However, candidate patients who wish to retain their prostate should be informed about the long term need to manage outflow obstructive symptoms.
Source of Funding: none e1276
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